PDF下载 ( 223 KB)
Basic management of nonalcoholic fatty liver disease
-
-
[1]Fan JG, Zhu J, Li XJ, et al.Prevalence of and risk factors for fatty liver in a general population of Shanghai, China[J].J Hepatol, 2005, 43 (3) :508-514. [2]Amarapurkar DN, Hashimoto E, Lesmana LA, et al.How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences-[J].J Gastroenterol Hepatol, 2007, 22 (6) :788-793. [3]Ekstedt M, Franzen LE, Mathiesen UL, et al.Long-term follow-up of patients with NAFLD and elevated liver enzymes[J].Hepatolo-gy, 2006, 44 (4) :865-873. [4]Wong VW, Chan HL, Hui AY, et al.Clinical and histological fea-tures of non-alcoholic fatty liver disease in Hong Kong Chinese[J].Aliment Pharmacol Ther, 2004, 20 (1) :45-49. [5]Hui AY, Wong VW, Chan HL, et al.Histological progression of non-alcoholic fatty liver disease in Chinese patients[J].Aliment Phar-macol Ther, 2005, 21 (4) :407-413. [6]Farrell GC, Chitturi S, Lau GK, et al.Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region:executive summary[J].J Gastroenterol Hepatol, 2007, 22 (6) :775-777. [7]Wong VW, Hui AY, Tsang SW, et al.Metabolic and adipokine pro-file of Chinese patients with nonalcoholic fatty liver disease[J].Clin Gastroenterol Hepatol, 2006, 4 (9) :1154-1161. [8]Targher G, Bertolini L, Rodella S, et al.Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type2diabetic patients[J].Diabetes Care, 2007, 30 (8) :2119-2121. [9]Wong VW, Hui AY, Tsang SW, et al.Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease[J].Aliment Pharmacol Ther, 2006, 24 (8) :1215-1222. [10]Merriman RB, Ferrell LD, Patti MG, et al.Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease[J].Hepatology, 2006, 44 (4) :874-880. [11]Chan HL.Non-invasive assessment of NAFLD[J].J Clin Hepa-tol, 2010, 26 (1) . [12]Feldstein AE, Wieckowska A, Lopez AR, et al.Cytokeratin-18fragment levels as noninvasive biomarkers for nonalcoholic steatohepa-titis:a multicenter validation study[J].Hepatology, 2009, 50 (4) :1072-1078. [13]Wong VW, Verginol J, Wong GL, et al.Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease[J].Hepatology, 2010, 51 (2) :454-462. [14]Knowler WC, Barrett-Connor E, Fowler SE.Reduction in the in-cidence of type2diabetes with lifestyle intervention or metformin[J].N Engl J Med, 2002, 346 (6) :393-403. [15]Musso G, Gambino R, De Michieli F, et al.Dietary habits and their relations to insulin resistance and postprandial lipemia in nonal-coholic steatohepatitis[J].Hepatology, 2003, 37 (4) :909-916. [16]Solga S, Alkhuraishe AR, Clark JM, et al.Diehl AM, Magnuson T.Dietary composition and nonalcoholic fatty liver disease[J].Dig Dis Sci, 2004, 49 (10) :1578-1583. [17]Cortez-Pinto H, Jesus L, Barros H, et al.Howdifferent is the di-etary pattern in non-alcoholic steatohepatitis patients-[J].Clin Nutr, 2006, 25 (5) :816-823. [18]Ouyang X, Cirillo P, Sautin Y, et al.Fructose consumption as a risk factor for non-alcoholic fatty liver disease[J].J Hepatol, 2008, 48 (6) :993-999. [19]Cortez-Pinto H, Chatham J, Chacko VP, et al.Alterations in liv-er ATP homeostasis in human nonalcoholic steatohepatitis:a pilot study[J].JAMA, 1999, 282 (17) :1659-1664. [20]Daubioul CA, Horsmans Y, Lambert P, et al.Effects of oligofruc-tose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis:results of a pilot study[J].Eur J Clin Nutr, 2005, 59 (5) :723-726. [21]Gasteyger C, Larsen TM, Vercruysse F, et al.Effect of a dietary-induced weight loss on liver enzymes in obese subjects[J].Am J Clin Nutr, 2008, 87 (5) :1141-1147. [22]St George A, Bauman A, Johnston A, et al.Effect of a lifestyle in-tervention in patients with abnormal liver enzymes and metabolic risk factors[J].J Gastroenterol Hepatol, 2009, 24 (3) :399-407. [23]Huang MA, Greenson JK, Chao C, et al.One-year intense nutri-tional counseling results in histological improvement in patients with non-alcoholic steatohepatitis:a pilot study[J].Am J Gastroen-terol, 2005, 100 (5) :1072-1081. [24]Kirk E, Reeds DN, Finck BN, et al.Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction[J].Gastroenterology, 2009, 136 (5) :1552-1560. [25]Shai I, Schwarzfuchs D, Henkin Y, et al.Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet[J].N Engl J Med, 2008, 359 (3) :229-241. [26]Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, et al.Role of leisure-time physical activity in nonalcoholic fatty liver disease:a population-based study[J].Hepatology, 2008, 48 (6) :1791-1798. [27]Kugelmas M, Hill DB, Vivian B, et al.Cytokines and NASH:a pilot study of the effects of lifestyle modification and vitamin E[J].Hepatology, 2003, 38 (2) :413-419. [28]Hickman IJ, Jonsson JR, Prins JB, et al.Modest weight loss andphysical activity in overweight patients with chronic liver disease re-sults in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life[J].Gut, 2004, 53 (3) :413-419. [29]Osland EJ, Powell EE, Banks M, et al.Obesity management in liver clinics:translation of research into clinical practice[J].J Gas-troenterol Hepatol, 2007, 22 (4) :504-509. [30]St George A, Bauman A, Johnston A, et al.Independent effects of physical activity in patients with nonalcoholic fatty liver disease[J].Hepatology, 2009, 50 (1) :68-76. [31]Johnson NA, Sachinwalla T, Walton DW, et al.Aerobic exercise training reduces hepatic and visceral lipids in obese individuals with-out weight loss[J].Hepatology, 2009, 50 (4) :1105-1112. [32]Harrison SA, Torgerson S, Hayashi P, et al.Vitamin E and vita-min C treatment improves fibrosis in patients with nonalcoholic steato-hepatitis[J].Am J Gastroenterol, 2003, 98 (11) :2485-2490. [33]Ersoz G, Gunsar F, Karasu Z, et al.Management of fatty liver dis-ease with vitamin E and C compared to ursodeoxycholic acid treat-ment[J].Turk J Gastroenterol, 2005, 16 (3) :124-128. [34]Nobili V, Manco M, Devito R, et al.Lifestyle intervention and an-tioxidant therapy in children with nonalcoholic fatty liver disease:a randomized, controlled trial[J].Hepatology, 2008, 48 (1) :119-128. [35]Santos VN, Lanzoni VP, Szejnfeld J, et al.Arandomized double-blind study of the short-time treatment of obese patients with nonal-coholic fatty liver disease with ursodeoxycholic acid[J].Braz J Med Biol Res, 2003, 36 (6) :723-729. [36]Lindor KD, Kowdley KV, Heathcote EJ, et al.Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis:results of a random-ized trial[J].Hepatology, 2004, 39 (3) :770-778. [37]Bugianesi E, Gentilcore E, Manini R, et al.A randomized con-trolled trial of metformin versus vitamin E or prescriptive diet in non-alcoholic fatty liver disease[J].Am J Gastroenterol, 2005, 100 (5) :1082-1090. [38]Nair S, Diehl AM, Wiseman M, et al.Metformin in the treatment of non-alcoholic steatohepatitis:a pilot open label trial[J].Ali-ment Pharmacol Ther, 2004, 20 (1) :23-28. [39]Sanyal AJ, Mofrad PS, Contos MJ, et al.Apilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis[J].Clin Gastroenterol Hepatol, 2004, 2 (12) :1107-1115. [40]Belfort R, Harrison SA, Brown K, et al.Aplacebo-controlled tri-al of pioglitazone in subjects with nonalcoholic steatohepatitis[J].N Engl J Med, 2006, 355 (22) :2297-2307. [41]Ratziu V, Giral P, Jacqueminet S, et al.Rosiglitazone for nonalco-holic steatohepatitis:one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial[J].Gastroenterology, 2008, 135 (1) :100-110. [42]Aithal GP, Thomas JA, Kaye PV, et al.Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalco-holic steatohepatitis[J].Gastroenterology, 2008, 135 (4) :1176-1184. [43]Lutchman G, Modi A, Kleiner DE, et al.The effects of discontinu-ing pioglitazone in patients with nonalcoholic steatohepatitis[J].Hepatology, 2007, 46 (2) :424-429. [44]Krall RL.Cardiovascular safety of rosiglitazone[J].Lancet, 2007, 369 (9578) :1995-1996. [45]Balas B, Belfort R, Harrison SA, et al.Pioglitazone treatment in-creases whole body fat but not total body water in patients with non-alcoholic steatohepatitis[J].J Hepatol, 2007, 47 (4) :565-570. [46]Jonsson JR, Clouston AD, Ando Y, et al.Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis[J].Gastroenterology, 2001, 121 (1) :148-155. [47]Yokohama S, Yoneda M, Haneda M, et al.Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis[J].Hepatology, 2004, 40 (5) :1222-1225. [48]Harrison SA, Fecht W, Brunt EM, et al.Orlistat for overweight subjects with nonalcoholic steatohepatitis:Arandomized, prospective trial[J].Hepatology, 2009, 49 (1) :80-86. [49]Osei-Hyiaman D, Liu J, Zhou L, et al.Hepatic CB1receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice[J].J Clin Invest, 2008, 118 (9) :3160-3169. [50]Gary-Bobo M, Elachouri G, Gallas JF, et al.Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syn-drome in obese Zucker fa/fa rats[J].Hepatology, 2007, 46 (1) :122-129. [51]Ekstedt M, Franzen LE, Mathiesen UL, et al.Statins in non-al-coholic fatty liver disease and chronically elevated liver enzymes:a histopathological follow-up study[J].J Hepatol, 2007, 47 (1) :135-141. [52]Lewis JH, Mortensen ME, Zweig S, et al.Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease:Results of a prospective, random-ized, double-blind, placebo-controlled, multicenter trial[J].Hepatology, 2007, 46 (5) :1453-1463. [53]Adams TD, Gress RE, Smith SC, et al.Long-term mortality after gastric bypass surgery[J].N Engl J Med, 2007, 357 (8) :753-761. [54]Sjostrom L, Narbro K, Sjostrom CD, et al.Effects of bariatric sur-gery on mortality in Swedish obese subjects[J].N Engl J Med, 2007, 357 (8) :741-752. [55]Mathurin P, Hollebecque A, Arnalsteen L, et al.Prospective study of the long-termeffects of bariatric surgery on liver injury in patients without advanced disease[J].Gastroenterology, 2009, 137 (2) :532-540. -
本文二维码
计量
- 文章访问数: 2947
- HTML全文浏览量: 14
- PDF下载量: 792
- 被引次数: 0
下载:
